Choreo LLC Has $900,000 Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Key Points

• Choreo LLC reduced its stake in Prestige Consumer Healthcare Inc. by 25.7%, selling 3,627 shares and holding a total of 10,473 shares valued at approximately $900,000.
• Several institutional investors have increased their positions in Prestige Consumer Healthcare, with JPMorgan Chase & Co. leading by acquiring a 44.5% increase in shares, now owning 393,474 shares worth $30.7 million.
• The stock received a favorable rating change from Wall Street analysts, with an average rating of "Moderate Buy" and a consensus target price of $93.33.

Choreo LLC lowered its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 25.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,473 shares of the company's stock after selling 3,627 shares during the period. Choreo LLC's holdings in Prestige Consumer Healthcare were worth $900,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Cerity Partners LLC boosted its position in Prestige Consumer Healthcare by 3.7% during the first quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock worth $315,000 after purchasing an additional 132 shares during the period. Franklin Resources Inc. boosted its position in Prestige Consumer Healthcare by 0.7% during the fourth quarter. Franklin Resources Inc. now owns 21,735 shares of the company's stock worth $1,697,000 after purchasing an additional 150 shares during the period. KBC Group NV increased its position in Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after buying an additional 151 shares during the period. CIBC Private Wealth Group LLC increased its position in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the period. Finally, McIlrath & Eck LLC increased its position in Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after buying an additional 154 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Analysts Set New Price Targets

PBH has been the topic of several recent analyst reports. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $93.33.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded up $0.55 during trading hours on Wednesday, reaching $75.20. The company had a trading volume of 525,021 shares, compared to its average volume of 400,791. The stock has a 50-day moving average of $81.11 and a two-hundred day moving average of $82.29. Prestige Consumer Healthcare Inc. has a one year low of $64.94 and a one year high of $90.04. The firm has a market capitalization of $3.72 billion, a PE ratio of 17.53, a PEG ratio of 2.24 and a beta of 0.43. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The firm had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same period in the prior year, the business posted $1.02 earnings per share. The business's revenue was up 7.0% compared to the same quarter last year. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.